Kinga Jurczak
Kinga Jurczak has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Anna Szlachcic
Captor Therapeutics Inc. Wrocław Poland
4 shared publications Daria Gajewska
Captor Therapeutics Inc. Wrocław Poland
4 shared publications- Janusz Wiśniewski
Captor Therapeutics Inc. Wrocław Poland
4 shared publications Kamil Przytulski
Captor Therapeutics Inc. Wrocław Poland
4 shared publications- Marta Klejnot
Captor Therapeutics Inc. Wrocław Poland
4 shared publications - Michal J. Walczak
Captor Therapeutics Inc. Wrocław Poland
4 shared publications
Latest Publications
- 14 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7)
Cover Feature: Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4 (ChemMedChem 7/2026)
- 14 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7)
Cover Feature: Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4 (ChemMedChem 7/2026)
- Open Access
- 3 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7) , e202500849
Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation is currently constrained by the limited availability of low‐molecular‐weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (von Hippel–Lindau ligase). In this study, we present the structure‐based drug design of high‐affinity ligands that engage E3 ligase GID4 (glucose‐induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis‐targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro, degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein–protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates.
- 3 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7) , e202500849
Open AccessLigand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation is currently constrained by the limited availability of low‐molecular‐weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (von Hippel–Lindau ligase). In this study, we present the structure‐based drug design of high‐affinity ligands that engage E3 ligase GID4 (glucose‐induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis‐targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro, degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein–protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates.
- Open Access
Ligand-induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation (TPD) is currently constrained by the limited availability of low-molecular-weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (Von Hippel-Lindau ligase). In this study, we present the structure-based drug design (SBDD) of high-affinity ligands that engage E3 ligase GID4 (Glucose-induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis-targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro , degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein-protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates. GRAPHICAL
Open AccessLigand-induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation (TPD) is currently constrained by the limited availability of low-molecular-weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (Von Hippel-Lindau ligase). In this study, we present the structure-based drug design (SBDD) of high-affinity ligands that engage E3 ligase GID4 (Glucose-induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis-targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro , degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein-protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates. GRAPHICAL
- Open Access
Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC
Targeted Protein Degradation (TPD) technology, in the form of CRBN-modulating molecular glues, offers numerous unprecedented therapeutic benefits as evidenced by the success of approved high-value immunomodulatory imide drugs (IMiDs) such as lenalidomide and pomalidomide. Building upon these successes, we employed a small CRBN-focused library of molecular glues in a phenotypic screen against hepatocellular carcinoma (HCC) cell lines. While the original library was primarily designed to target SALL4, we identified additional CRBN substrates, including GSPT1, NEK7, and CK1 α , whose degradation potently induced cell death in HCC cell lines. Subsequent lead optimization efforts yielded a compound, ABS-752, which demonstrated superior in vitro and in vivo activity through the potent degradation of GSPT1. Notably, ABS-752 does not form ternary complexes with CRBN and the neosubstrates. Further investigations revealed that ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002. VAP-1, which is overexpressed in cirrhotic liver, was identified as the primary monoamine oxidase responsible for the conversion of ABS-752. ABS-752 is currently in clinical trials for the treatment of HCC.
Open AccessTargeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC
Targeted Protein Degradation (TPD) technology, in the form of CRBN-modulating molecular glues, offers numerous unprecedented therapeutic benefits as evidenced by the success of approved high-value immunomodulatory imide drugs (IMiDs) such as lenalidomide and pomalidomide. Building upon these successes, we employed a small CRBN-focused library of molecular glues in a phenotypic screen against hepatocellular carcinoma (HCC) cell lines. While the original library was primarily designed to target SALL4, we identified additional CRBN substrates, including GSPT1, NEK7, and CK1 α , whose degradation potently induced cell death in HCC cell lines. Subsequent lead optimization efforts yielded a compound, ABS-752, which demonstrated superior in vitro and in vivo activity through the potent degradation of GSPT1. Notably, ABS-752 does not form ternary complexes with CRBN and the neosubstrates. Further investigations revealed that ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002. VAP-1, which is overexpressed in cirrhotic liver, was identified as the primary monoamine oxidase responsible for the conversion of ABS-752. ABS-752 is currently in clinical trials for the treatment of HCC.